Medigen Vaccine Biologics (6547) - Total Liabilities

Latest as of December 2025: NT$454.64 Million TWD ≈ $14.32 Million USD

Based on the latest financial reports, Medigen Vaccine Biologics (6547) has total liabilities worth NT$454.64 Million TWD (≈ $14.32 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Medigen Vaccine Biologics (6547) cash conversion ratio to assess how effectively this company generates cash.

Medigen Vaccine Biologics - Total Liabilities Trend (2012–2025)

This chart illustrates how Medigen Vaccine Biologics's total liabilities have evolved over time, based on quarterly financial data. Check how resilient are Medigen Vaccine Biologics's assets to evaluate the company's liquid asset resilience ratio.

Medigen Vaccine Biologics Competitors by Total Liabilities

The table below lists competitors of Medigen Vaccine Biologics ranked by their total liabilities.

Company	Country	Total Liabilities
HCR Co Ltd SHG:688500	China	CN¥275.44 Million
Donegal Group A Inc NASDAQ:DGICA	USA	$1.75 Billion
Chongqing Mas Sci&Tech SHE:300275	China	CN¥451.37 Million
Hwail Pharmaceutical Co.Ltd KQ:061250	Korea	₩5.29 Billion
Lumibird SA PA:LBIRD	France	€236.13 Million
Trakcja PRKiI S.A. WAR:TRK	Poland	zł1.26 Billion
Tangel Publishing SHE:300148	China	CN¥316.83 Million

Liability Composition Analysis (2012–2025)

This chart breaks down Medigen Vaccine Biologics's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market value of Medigen Vaccine Biologics.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	12.77	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.13	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.12	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Medigen Vaccine Biologics's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Medigen Vaccine Biologics (2012–2025)

The table below shows the annual total liabilities of Medigen Vaccine Biologics from 2012 to 2025.

Year	Total Liabilities	Change
2025-12-31	NT$454.64 Million ≈ $14.32 Million	-11.53%
2024-12-31	NT$513.92 Million ≈ $16.19 Million	-77.12%
2023-12-31	NT$2.25 Billion ≈ $70.76 Million	-3.13%
2022-12-31	NT$2.32 Billion ≈ $73.05 Million	+272.21%
2021-12-31	NT$622.95 Million ≈ $19.63 Million	+78.29%
2020-12-31	NT$349.40 Million ≈ $11.01 Million	-61.62%
2019-12-31	NT$910.28 Million ≈ $28.68 Million	+59.39%
2018-12-31	NT$571.10 Million ≈ $17.99 Million	-7.20%
2017-12-31	NT$615.41 Million ≈ $19.39 Million	+76.89%
2016-12-31	NT$347.90 Million ≈ $10.96 Million	+12.52%
2015-12-31	NT$309.19 Million ≈ $9.74 Million	+127.43%
2014-12-31	NT$135.95 Million ≈ $4.28 Million	+598.49%
2013-12-31	NT$19.46 Million ≈ $613.19K	-12.13%
2012-12-31	NT$22.15 Million ≈ $697.85K	--

About Medigen Vaccine Biologics

TWO:6547 Taiwan Biotechnology

Market Cap

$513.21 Million

NT$16.29 Billion TWD

Market Cap Rank

#12422 Global

#441 in Taiwan

Share Price

NT$49.55

Change (1 day)

-0.70%

52-Week Range

NT$33.75 - NT$61.00

All Time High

NT$280.20